NAT2
Gastrointestinal & Hepatic System · Phase I & Phase II Xenobiotic Detoxification
What does being a slow acetylator mean for NAT2?
NAT2 makes an enzyme that chemically modifies certain drugs and other compounds. A slow-acetylator result describes reduced activity in that pathway, with practical implications that depend on the substance involved.
- Common Gene Name
- N-acetyltransferase 2
- NCBI Gene ID
- 10
- Chromosome
- 8
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (3 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Amifampridine | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Amifampridine Phosphate | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Amifampridine Phosphate | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Neurology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Gastrointestinal & Hepatic System